Antiviral activity of the EB peptide against zoonotic poxviruses
© Altmann et al; BioMed Central Ltd. 2011
Received: 2 November 2011
Accepted: 6 January 2012
Published: 6 January 2012
The EB peptide is a 20-mer that was previously shown to have broad spectrum in vitro activity against several unrelated viruses, including highly pathogenic avian influenza, herpes simplex virus type I, and vaccinia, the prototypic orthopoxvirus. To expand on this work, we evaluated EB for in vitro activity against the zoonotic orthopoxviruses cowpox and monkeypox and for in vivo activity in mice against vaccinia and cowpox.
In yield reduction assays, EB had an EC50 of 26.7 μM against cowpox and 4.4 μM against monkeypox. The EC50 for plaque reduction was 26.3 μM against cowpox and 48.6 μM against monkeypox. A scrambled peptide had no inhibitory activity against either virus. EB inhibited cowpox in vitro by disrupting virus entry, as evidenced by a reduction of the release of virus cores into the cytoplasm. Monkeypox was also inhibited in vitro by EB, but at the attachment stage of infection. EB showed protective activity in mice infected intranasally with vaccinia when co-administered with the virus, but had no effect when administered prophylactically one day prior to infection or therapeutically one day post-infection. EB had no in vivo activity against cowpox in mice.
While EB did demonstrate some in vivo efficacy against vaccinia in mice, the limited conditions under which it was effective against vaccinia and lack of activity against cowpox suggest EB may be more useful for studying orthopoxvirus entry and attachment in vitro than as a therapeutic against orthopoxviruses in vivo.
The EB peptide (NH2- RRKKAAVALLPAVLLALLAP-COOH) is a 20-mer derived from the signal peptide of the human FGF4 protein  and was originally identified as an inhibitor of herpes simplex virus entry . Subsequent work demonstrated that EB was active against several strains of influenza virus both in vitro and in vivo , with a minimum of 13 core amino acids being identified as necessary to block influenza attachment to host cells . EB was also identified as an inhibitor of Vaccinia virus entry into host cells in vitro . This broad range of antiviral activity against a number of unrelated viruses, in combination with low in vivo toxicity , makes EB an attractive candidate for a broad-spectrum antiviral therapy.
Vaccinia virus (VACV) is the most-studied member of the orthopoxviruses, a genus of large, double-stranded DNA virus whose most notorious member, Variola virus, the etiologic agent of smallpox, was declared eradicated in 1980 . Vaccinia virus infection typically results in a self-limiting infection in immunocompetent individuals; the closely-related cowpox (CPXV) and monkeypox (MPXV) viruses, however, are both considered to be emerging zoonotic agents [8, 9] with the potential to cause serious morbidity and, in the case of MPXV, mortality in infected hosts . There are currently no FDA-approved therapeutics for treating orthopoxvirus infections, and vaccination is counter-indicated for an increasingly large percentage of the global population, highlighting the need for novel therapeutic options. The relatively low global incidence of severe orthopoxvirus disease, however, makes identifying broad spectrum drugs with activity against a number of unrelated viruses, including the orthopoxviruses, economically advantageous. To expand upon the initial characterization of EB peptide anti-orthopoxvirus activity, the goals of this work were to test EB for efficacy against CPXV and MPXV in vitro, to begin to determine the mechanism for any inhibition observed, and to test EB for in vivo activity in two well-characterized mouse models of orthopoxvirus disease, VACV and CPXV.
In summary, we were able to demonstrate in vivo efficacy of EB against VACV but not CPXV, despite both viruses having similar sensitivities to the peptide in vitro. The reasons for this difference are as yet unclear. EB was only effective against VACV when co-administered with the virus, suggesting that the peptide needed direct interaction with the virus to be effective. EB self-associates in micelle-like structures at high concentrations and in high ionic buffers , a property which could influence bioavailability. It is possible that the in vivo anti-orthopoxvirus activity could therefore be improved by changing the vehicle used for delivery.
Most intriguing is the observation that EB inhibited attachment by MPXV but blocked entry by CPXV, as these processes are generally believed to be highly conserved between the orthopoxviruses. While EB has now been shown to have activity in vivo against VACV and influenza viruses , its greatest potential with orthopoxviruses may be as a novel in vitro tool to study the poorly-characterized early steps in infection. To date, over a dozen viral proteins are believed to be involved in orthopoxvirus attachment and entry [13–25]. The precise mechanisms of attachment and entry, however, have yet to be elucidated. Identification of the precise targets of the interaction between EB and VACV, CPXV, and MPXV could help identify key amino acids or structural features necessary for these processes and identify targets for novel inhibitors of infection.
The authors thank Grant McFadden (University of Florida) for the gift of the cowpox-GFP virus and Roselyn Eisenberg and Gary Cohen for the R236 anti-core antibody. The authors thank Russ Byrum, Isis Alexander and Bernardo Rosa for technical assistance. This work was supported in part by the NIAID Division of Intramural Research and by grants AI52049 and EYP30-016665 to Curtis R. Brandt. All animal work was performed under a NIAID-approved protocol and in compliance with NIAID's Institutional Animal Care and Use Committee.
- Lin Y-Z, Yao S, Veach RA, Torgerson TR, Hawiger J: Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995, 270: 14255-14258. 10.1074/jbc.270.24.14255PubMedView ArticleGoogle Scholar
- Bultmann H, Busse JS, Brandt CR: Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J Virol 2001, 75: 2634-2645. 10.1128/JVI.75.6.2634-2645.2001PubMedPubMed CentralView ArticleGoogle Scholar
- Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S: Inhibition of influenza virus infection by a novel antiviral peptide that targets attachment to cells. J Virol 2006, 80: 11960-11967. 10.1128/JVI.01678-06PubMedPubMed CentralView ArticleGoogle Scholar
- Jones JC, Settles EW, Brandt CR, Schultz-Cherry S: Identification of the minimal active sequence of an anti-influenza virus peptide. Antimicrob Agents Chemother 2011, 55: 1810-1813. 10.1128/AAC.01428-10PubMedPubMed CentralView ArticleGoogle Scholar
- Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR: Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology 2009, 388: 248-259. 10.1016/j.virol.2009.03.023PubMedPubMed CentralView ArticleGoogle Scholar
- Akkarawongsa R, Cullinan AE, Zinkel A, Clarin J, Brandt CR: Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry. J Ocul Pharmacol Ther 2006, 22: 279-289. 10.1089/jop.2006.22.279PubMedView ArticleGoogle Scholar
- WHO: Declaration of global eradication of smallpox. Weekly Epidemiol Rec 1980, 55: 148.Google Scholar
- Essbauer S, Pfeffer M, Meyer H: Zoonotic poxviruses. Vet Microbiol 2010, 140: 229-236. 10.1016/j.vetmic.2009.08.026PubMedView ArticleGoogle Scholar
- Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, et al.: Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the democratic republic of Congo. Proc Natl Acad Sci USA 2010, 107: 16262-16267. 10.1073/pnas.1005769107PubMedPubMed CentralView ArticleGoogle Scholar
- Ježek Z, Fenner F: Human Monkeypox. New York: Karger; 1988.Google Scholar
- Law M, Smith GL: Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. Methods Mol Biol 2004, 269: 187-204.PubMedGoogle Scholar
- Bultmann H, Girdaukas G, Kwon GS, Brandt CR: The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner. Antimicrob Agents Chemother 2010, 54: 4275-4289. 10.1128/AAC.00495-10PubMedPubMed CentralView ArticleGoogle Scholar
- Chung CS, Hsiao JC, Chang YS, Chang W: A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998, 72: 1577-1585.PubMedPubMed CentralGoogle Scholar
- Hsiao JC, Chung CS, Chang W: Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999, 73: 8750-8761.PubMedPubMed CentralGoogle Scholar
- Senkevich TG, Ward BM, Moss B: Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol 2004, 78: 2357-2366. 10.1128/JVI.78.5.2357-2366.2004PubMedPubMed CentralView ArticleGoogle Scholar
- Senkevich TG, Moss B: Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol 2005, 79: 4744-4754. 10.1128/JVI.79.8.4744-4754.2005PubMedPubMed CentralView ArticleGoogle Scholar
- Senkevich TG, Ojeda S, Townsley A, Nelson GE, Moss B: Poxvirus multiprotein entry-fusion complex. PNAS 2005, 102: 18572-18577. 10.1073/pnas.0509239102PubMedPubMed CentralView ArticleGoogle Scholar
- Townsley AC, Senkevich TG, Moss B: Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol 2005, 79: 9458-9469. 10.1128/JVI.79.15.9458-9469.2005PubMedPubMed CentralView ArticleGoogle Scholar
- Townsley AC, Senkevich TG, Moss B: The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol 2005, 79: 10988-10998. 10.1128/JVI.79.17.10988-10998.2005PubMedPubMed CentralView ArticleGoogle Scholar
- Brown E, Senkevich TG, Moss B: Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol 2006, 80: 9455-9464. 10.1128/JVI.01149-06PubMedPubMed CentralView ArticleGoogle Scholar
- Izmailyan RA, Huang CY, Mohammad S, Isaacs SN, Chang W: The envelope G3L protein is essential for entry of vaccinia virus into host cells. J Virol 2006, 80: 8402-8410. 10.1128/JVI.00624-06PubMedPubMed CentralView ArticleGoogle Scholar
- Ojeda S, Domi A, Moss B: Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol 2006, 80: 9822-9830. 10.1128/JVI.00987-06PubMedPubMed CentralView ArticleGoogle Scholar
- Bisht H, Weisberg AS, Moss B: Vaccinia virus L1 protein is required for cell entry and membrane fusion. J Virol 2008, 82: 8687-8694. 10.1128/JVI.00852-08PubMedPubMed CentralView ArticleGoogle Scholar
- Nichols RJ, Stanitsa E, Unger B, Traktman P: The Vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry. J Virol 2008, 82: 10247-10261. 10.1128/JVI.01035-08PubMedPubMed CentralView ArticleGoogle Scholar
- Satheshkumar PS, Moss B: Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol 2009, 83: 12822-12832. 10.1128/JVI.01744-09PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.